Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Doris K. Hansen, Lauren C. Peres, Danai Dima, Alicia Richards, Leyla O. Shune, Aimaz Afrough, Shonali Midha, Binod Dhakal, Mehmet H. Kocoglu, Shebli Atrash, Chris Ferreri, Omar Castaneda, James A Davis, Evguenia Ouchveridze, Joseph P. McGuirk, Charlotte B Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Laura B. Oswald, Gurbakhash Kaur, Oren Pasvolsky, Mahmoud R. Gaballa, Megan M Herr, Peter A. Forsberg, Murali Janakiram, Myo Htut, Sireesha Asoori, Nilesh Kalariya, Hamza Hashmi, Ran Reshef, Douglas W Sborov, Omar Nadeem, Faiz Anwer, Jack Khouri, Shahzad Raza, Djordje Atanackovic, Melissa Alsina, Ciara Louise Freeman, Frederick L. Locke, Peter M. Voorhees, Larry D Anderson, Jr., Shambavi Richard, Thomas Martin, Yi Lin, Krina K. Patel, Surbhi Sidana

Blood (2024) 144 (Supplement 1): 936.

https://doi.org/10.1182/blood-2024-194390

Published: 2024

Journal Articles

Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 931.

https://doi.org/10.1182/blood-2024-202017

Published: 2024

Journal Articles

Efficacy of Stem Cell Boost (SCB) for Chimeric Antigen Receptor T Cell (CAR-T)-Related Hematologic Toxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)- a Multi-Center Real World Experience

Blood (2024) 144 (Supplement 1): 4712.

https://doi.org/10.1182/blood-2024-204257

Published: 2024

Journal Articles

Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium

Blood (2024) 144 (Supplement 1): 3765.

https://doi.org/10.1182/blood-2024-199609

Published: 2024

Journal Articles

Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel

Lauren C. Peres, Alicia Richards, Surbhi Sidana, Laura B. Oswald, Danai Dima, Aimaz Afrough, Leyla O. Shune, Shonali Midha, Omar Castaneda, Christopher Ferreri, James A Davis, Oren Pasvolsky, Christen M. Dillard, Megan M Herr, Mehmet H. Kocoglu, Shebli Atrash, Brandon Blue, Evguenia Ouchveridze, Joseph P. McGuirk, Charlotte B Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Gurbakhash Kaur, Mahmoud R. Gaballa, Peter A. Forsberg, Ciara Louise Freeman, Murali Janakiram, Myo Htut, Sireesha Asoori, Nilesh Kalariya, Djordje Atanackovic, Binod Dhakal, Jack Khouri, Shahzad Raza, Ran Reshef, Melissa Alsina, Frederick L. Locke, Omar Nadeem, Faiz Anwer, Larry D Anderson, Jr., Shambavi Richard, Yi Lin, Thomas Martin, Peter M. Voorhees, Krina K. Patel, Doris K. Hansen, Douglas W Sborov

Blood (2024) 144 (Supplement 1): 3785.

https://doi.org/10.1182/blood-2024-210078

Published: 2024

Journal Articles

Evaluation of Pharmacist-Managed Thiopurine-Based Leukemia Maintenance Service Via a Collaborative Practice Agreement

Taylor Kujawa, Charlotte B Wagner, Alexis Riddle, Jordan Robeson, Laura Bickel, Andrea Schindler, Srinivas K Tantravahi, Paul J. Shami

Blood (2024) 144 (Supplement 1): 5026.

https://doi.org/10.1182/blood-2024-198034

Published: 2024

Journal Articles

Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma

James A Davis, Jordan Snyder, Mikhaila Rice, Donald C Moore, Christopher Cahoon, Kelley Julian, Charlotte B Wagner, Katelynn Granger, Kimberly M Green, Shebli Atrash, Hailey Hill, Jessica McElwee, Grace Elsey, Jack Khouri, Joslyn Rudoni, Zahra Mahmoudjafari, Victoria Nachar

Blood (2024) 144 (Supplement 1): 2382.

https://doi.org/10.1182/blood-2024-193025

Published: 2024

Journal Articles

Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3499.

https://doi.org/10.1182/blood-2023-187565

Published: 2023

Journal Articles

Relapsed and Refractory Multiple Myeloma with Pleural Involvement: A Case Series

Douglas Peters, Victoria A. Vardell, Gliceida Galarza Fortuna, Sterling Rosqvist, Charlotte B Wagner, Kelley Julian, Baylee Bryan, Mary Nicole Steinbach, Samuel Shewan, Lindsay Maxwell, Brian McClune, Amandeep Godara, Ghulam Rehman Mohyuddin, Matthew F Covington, Douglas Sborov

Blood (2023) 142 (Supplement 1): 6630.

https://doi.org/10.1182/blood-2023-179287

Published: 2023

Journal Articles

High Rates of Thrombotic Events in Newly Diagnosed Multiple Myeloma Patients Enrolled on the Maia Trial

Sterling Rosqvist, Victoria A. Vardell, Eric Anto, Gliceida Galarza Fortuna, Douglas Peters, Charlotte B Wagner, Baylee Bryan, Mary Nicole Steinbach, Samuel Shewan, Lindsay Maxwell, Michael R. Savona, Kelley Julian, Brian McClune, Ghulam Rehman Mohyuddin, Amandeep Godara, Muhamed Baljevic, Douglas Sborov

Blood (2023) 142 (Supplement 1): 4718.

https://doi.org/10.1182/blood-2023-190746

Published: 2023

Journal Articles

Carfilzomib in Combination with Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin (KDCEP) for the Treatment of Relapsed/Refractory Aggressive Plasma Cell Dyscrasias

Charlotte B Wagner, Kelley Julian, Baylee Bryan, Mary Nicole Steinbach, Samuel Shewan, Lindsay Maxwell, Meghan Vigil, Ghulam Rehman Mohyuddin, Amandeep Godara, Brian McClune, Douglas Sborov

Blood (2023) 142 (Supplement 1): 6623.

https://doi.org/10.1182/blood-2023-174123

Published: 2023

Journal Articles

Fludarabine Lymphodepletion Exposure Is Associated with Idecabtagene Vicleucel Toxicity in Relapsed and Refractory Multiple Myeloma Patients: Real-World Experience from the US Myeloma Immunotherapy Consortium

Blood (2023) 142 (Supplement 1): 4880.

https://doi.org/10.1182/blood-2023-187440

Published: 2023

Journal Articles

Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience

Blood (2022) 140 (Supplement 1): 10427–10429.

https://doi.org/10.1182/blood-2022-163464

Published: 2022

Journal Articles

CAR-T Therapy in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: Real World Outcomes Based on Tumor Biology

Luke Brinkman, Charlotte B Wagner, Jian Ying, Martina Fraga, Bernard L. Marini, Gianni Bruno Scappaticci, Jonathan Ptachcinski, Sagar S. Patel

Blood (2022) 140 (Supplement 1): 9546–9547.

https://doi.org/10.1182/blood-2022-170317

Published: 2022

Journal Articles

Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy

Blood (2022) 140 (Supplement 1): 623–625.

https://doi.org/10.1182/blood-2022-158478

Published: 2022

Journal Articles

Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival

Blood (2022) 140 (Supplement 1): 9390–9392.

https://doi.org/10.1182/blood-2022-159001

Published: 2022

Journal Articles

Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience

Blood (2022) 140 (Supplement 1): 4642–4645.

https://doi.org/10.1182/blood-2022-164828

Published: 2022

Journal Articles

Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience

Blood (2022) 140 (Supplement 1): 10377–10379.

https://doi.org/10.1182/blood-2022-166058

Published: 2022

Journal Articles

Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience

Blood (2022) 140 (Supplement 1): 1856–1858.

https://doi.org/10.1182/blood-2022-164884

Published: 2022

Journal Articles

Assessment of Midostaurin in Combination with Idarubicin-Based Induction Treatment in Acute Myeloid Leukemia

Julia Lee, Charlotte B Wagner, Stacy Prelewicz, Heena P Kurish, Rob Walchack, Danielle Cenin, Seema Patel, Mimi Lo, Danielle Schlafer, Belinda KT Li, R Donald Harvey, Bestis Wasef, Jian Ying, Tibor Kovacsovics

Blood (2022) 140 (Supplement 1): 3242–3243.

https://doi.org/10.1182/blood-2022-170123

Published: 2022

NARROW

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Efficacy of Stem Cell Boost (SCB) for Chimeric Antigen Receptor T Cell (CAR-T)-Related Hematologic Toxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)- a Multi-Center Real World Experience

Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium

Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel

Evaluation of Pharmacist-Managed Thiopurine-Based Leukemia Maintenance Service Via a Collaborative Practice Agreement

Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma

Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma

Relapsed and Refractory Multiple Myeloma with Pleural Involvement: A Case Series

High Rates of Thrombotic Events in Newly Diagnosed Multiple Myeloma Patients Enrolled on the Maia Trial

Carfilzomib in Combination with Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin (KDCEP) for the Treatment of Relapsed/Refractory Aggressive Plasma Cell Dyscrasias

Fludarabine Lymphodepletion Exposure Is Associated with Idecabtagene Vicleucel Toxicity in Relapsed and Refractory Multiple Myeloma Patients: Real-World Experience from the US Myeloma Immunotherapy Consortium

Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience

CAR-T Therapy in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: Real World Outcomes Based on Tumor Biology

Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy

Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival

Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience

Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience

Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience

Assessment of Midostaurin in Combination with Idarubicin-Based Induction Treatment in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only